Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
Nature Medicine2004Vol. 10(11), pp. 1240–1244
Citations Over TimeTop 1% of 2004 papers
Helen McShane, Ansar A. Pathan, Clare R. Sander, Sheila M. Keating, Sarah C. Gilbert, Kris Huygen, Helen A. Fletcher, Adrian V. S. Hill
Related Papers
- → Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials(2013)257 cited
- → The Mycobacterium tuberculosis PhoPR virulence system regulates expression of the universal second messenger c-di-AMP and impacts vaccine safety and efficacy(2022)15 cited
- → Vaccine efficacy of an attenuated but persistent Mycobacterium tuberculosis cysH mutant(2007)15 cited
- → Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected Individuals(2009)7 cited
- → Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis(2023)4 cited